Play all audios:
For the quarter ended March 31, the company posted revenue of ₹3,079 crore, up 27% year-on-year, with adjusted EBITDA margin at 23.1% and a net profit of ₹429 crore, down 10%, translating
into a net profit margin of 13.9%. Exports stood out with a 100% year-on-year jump, contributing ₹535 crore. Domestic revenue rose 18% to ₹2,544 crore.
On a full-year basis, Mankind recorded revenue of ₹12,207 crore, a 19% growth over FY24, and adjusted EBITDA of ₹3,159 crore at a margin of 25.9%. Domestic revenue crossed a key milestone at
₹10,675 crore, up 13% year-on-year, while exports jumped 88% to ₹1,532 crore.
Vice Chairman and managing director Rajeev Juneja called FY25 a “transformative year,” citing strategic moves such as the successful integration of recently acquired BSV, continued
outperformance in chronic segments, and operational efficiencies. He noted Mankind’s long-term strategy rests on four pillars: a steady base business, high-growth specialty chronic products,
a high-potential OTC segment, and BSV’s super-specialty portfolio.
Consumer healthcare grew 14% in the fourth quarter and 15% for the full year, reaching ₹809 crore, aided by strong secondary sales of Manforce Condoms, Gas-O-Fast, and HealthOK. New launches
in FY25 included Epic ThinX (unflavoured condom), Nimulid (pain relief), and OvaNews (ovulation test kit).
In exports, the company attributed the strong 100% fourth-quarter growth to a ramp-up in the base business and product launches in the last two years. Mankind has launched 44 products in the
U.S. market to date, with six introduced in FY25 alone.
Despite short-term headwinds in acute therapy due to regulatory issues, Mankind retained its top rank in prescriptions for the eighth consecutive year and continued to outperform the Indian
Pharmaceutical Market (IPM) in chronic categories—1.5x in cardiac and 1.3x in anti-diabetics.
Mankind also highlighted progress in operational scale and efficiency, supported by its 30 manufacturing facilities, seven R&D centres, and a field force of over 18,000 professionals. The
company’s reach spans more than five lakh doctors across India.
Mankind Pharma shares closed 0.75% lower at ₹2530 on the BSE.